Although the FDA officially removed tirzepatide from the shortage list in December 2024 and semaglutide in February 2025, compounded prescribing has not abated
Individuals with severe gastroparesis or significant gastrointestinal disease may be at greater risk of exacerbated symptoms and would need careful individual assessment before commencing treatment
This practice may increase the risk of dosing error and contamination
The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies
Previous clinical and preclinical studies have been contradictory, says co-corresponding author Yonggui Yuan of Southeast University in Jiangsu, China
Microdosing GLP1 in Menopause & Perimenopause What it is : Microdosing GLP-1 in menopause and perimenopause means using a lower, personalized dose of GLP-1 medication to gently support appetite control, energy, and focus